Abstract
S1P has been proposed to contribute to cancer progression by regulating tumor proliferation, invasion, and angiogenesis. We developed a biospecific monoclonal antibody to S1P to investigate its role in tumorigenesis. The anti-S1P mAb substantially reduced tumor progression and in some cases eliminated measurable tumors in murine xenograft and allograft models. Tumor growth inhibition was attributed to antiangiogenic and antitumorigenic effects of the antibody. The anti-S1P mAb blocked EC migration and resulting capillary formation, inhibited blood vessel formation induced by VEGF and bFGF, and arrested tumor-associated angiogenesis. The anti-S1P mAb also neutralized S1P-induced proliferation, release of proangiogenic cytokines, and the ability of S1P to protect tumor cells from apoptosis in several tumor cell lines, validating S1P as a target for therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 225-238 |
| Number of pages | 14 |
| Journal | Cancer Cell |
| Volume | 9 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 1 2006 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research
Cite this
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. / Visentin, Barbara; Vekich, John A.; Sibbald, Bradley J.; Cavalli, Amy L.; Moreno, Kelli M.; Matteo, Rosalia G.; Garland, William A.; Lu, Yiling; Yu, Shuangxing; Hall, Hassan S.; Kundra, Vikas; Mills, Gordon; Sabbadini, Roger A.
In: Cancer Cell, Vol. 9, No. 3, 01.03.2006, p. 225-238.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages
AU - Visentin, Barbara
AU - Vekich, John A.
AU - Sibbald, Bradley J.
AU - Cavalli, Amy L.
AU - Moreno, Kelli M.
AU - Matteo, Rosalia G.
AU - Garland, William A.
AU - Lu, Yiling
AU - Yu, Shuangxing
AU - Hall, Hassan S.
AU - Kundra, Vikas
AU - Mills, Gordon
AU - Sabbadini, Roger A.
PY - 2006/3/1
Y1 - 2006/3/1
N2 - S1P has been proposed to contribute to cancer progression by regulating tumor proliferation, invasion, and angiogenesis. We developed a biospecific monoclonal antibody to S1P to investigate its role in tumorigenesis. The anti-S1P mAb substantially reduced tumor progression and in some cases eliminated measurable tumors in murine xenograft and allograft models. Tumor growth inhibition was attributed to antiangiogenic and antitumorigenic effects of the antibody. The anti-S1P mAb blocked EC migration and resulting capillary formation, inhibited blood vessel formation induced by VEGF and bFGF, and arrested tumor-associated angiogenesis. The anti-S1P mAb also neutralized S1P-induced proliferation, release of proangiogenic cytokines, and the ability of S1P to protect tumor cells from apoptosis in several tumor cell lines, validating S1P as a target for therapy.
AB - S1P has been proposed to contribute to cancer progression by regulating tumor proliferation, invasion, and angiogenesis. We developed a biospecific monoclonal antibody to S1P to investigate its role in tumorigenesis. The anti-S1P mAb substantially reduced tumor progression and in some cases eliminated measurable tumors in murine xenograft and allograft models. Tumor growth inhibition was attributed to antiangiogenic and antitumorigenic effects of the antibody. The anti-S1P mAb blocked EC migration and resulting capillary formation, inhibited blood vessel formation induced by VEGF and bFGF, and arrested tumor-associated angiogenesis. The anti-S1P mAb also neutralized S1P-induced proliferation, release of proangiogenic cytokines, and the ability of S1P to protect tumor cells from apoptosis in several tumor cell lines, validating S1P as a target for therapy.
UR - http://www.scopus.com/inward/record.url?scp=33644830810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644830810&partnerID=8YFLogxK
U2 - 10.1016/j.ccr.2006.02.023
DO - 10.1016/j.ccr.2006.02.023
M3 - Article
C2 - 16530706
AN - SCOPUS:33644830810
VL - 9
SP - 225
EP - 238
JO - Cancer Cell
JF - Cancer Cell
SN - 1535-6108
IS - 3
ER -